Metastasis-directed Therapy (SBRT) Guided by PET-CT
Metastasis-directed therapy
Oligometastases
PSMA-PET
Prostate cancer
Stereotactic body radiation therapy
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
05
2020
revised:
27
07
2020
accepted:
01
08
2020
pubmed:
31
8
2020
medline:
19
8
2021
entrez:
1
9
2020
Statut:
ppublish
Résumé
The present analysis aims to compare the impact of 18F-fluorocholine ( Inclusion criteria were: (1) histologically proven prostate adenocarcinoma; (2) evidence of biochemical relapse after primary tumor treatment; (3) ≤ 3 hypermetabolic oligorecurrent lesions detected by A total of 118 lesions in 88 patients were analyzed. Forty-four (50%) patients underwent In the setting of oligorecurrent castration-sensitive PC, PSMA-PET-guided SBRT produced a higher rate of ADT-free patients when compared with the
Sections du résumé
BACKGROUND
The present analysis aims to compare the impact of 18F-fluorocholine (
MATERIALS AND METHODS
Inclusion criteria were: (1) histologically proven prostate adenocarcinoma; (2) evidence of biochemical relapse after primary tumor treatment; (3) ≤ 3 hypermetabolic oligorecurrent lesions detected by
RESULTS
A total of 118 lesions in 88 patients were analyzed. Forty-four (50%) patients underwent
CONCLUSION
In the setting of oligorecurrent castration-sensitive PC, PSMA-PET-guided SBRT produced a higher rate of ADT-free patients when compared with the
Identifiants
pubmed: 32863189
pii: S1558-7673(20)30191-9
doi: 10.1016/j.clgc.2020.08.002
pii:
doi:
Substances chimiques
Androgen Antagonists
0
Gallium Isotopes
0
Gallium Radioisotopes
0
gallium 68 PSMA-11
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
230-236Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.